Market Authorised Cannabis Medicines: The Future of Medical Cannabis?

There are over 200 medical cannabis products available in
Germany, yet only 2 of them have market authorisation, why is
that? Today's panel will be discussing why such few companies
have pursued drug development and market authorisation. What role
will approved finished drugs play in the future and what is the
impact of legalisation of recreational cannabis? Will legislation
affect the type of products available to patients? Our expert
panel will provide their insights on the future of the German
medical market.



Language: English



Speakers



Bijan Christoph Hezarkhani (Moderator),
BijanChristoph.com, Business Development


Ana Serrato (Speaker), Avextra Pharma, Head
Drug Development


Bertan Türemis (Speaker), Fette Pharma GmbH,
Medical Science Liaison


Maximilian Schmitt (Speaker), Cannaflos -
Gesellschaft für medizinisches Cannabis GmbH, Co-Founder &
CEO